Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.
Den 11 april 2018 observationsnoterades aktierna i Wilson Therapeutics AB ("Bolaget") med hänvisning till ett offentligt uppköpserbjudande från Alexion Pharmaceuticals Inc., genom dess dotterbolag ...
Ulrich Theinel has been appointed chief medical officer of Finch Therapeutics. Before joining the Somerville, MA, microbiome therapeutics developer, Theinel held leadership positions at Novelion Therapeutics, Eleven Biotherapeutics, ImmunoGen, Domantis, and Transkaryotic Therapies. Finch is currently in mid-stage clinical studies testing its microbial therapy as a treatment for Clostridium diffici...
Celsius Therapeutics, a company translating single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer, launched with a $65 million Series A financing led by Third Rock Ventures with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and other key investors. Celsius is charting a new course of...
UK-based drug discovery AdoRx Therapeutics has raised $10 million to fund its work on identifying new cancer therapeutics, in an investment round financed by Epidarex Capital and CRT Pioneer Fund.
Summit Therapeutics plc ('Summit' or the 'Company')Result of Annual General MeetingOxford, UK, and Cambridge, MA, US, 7 June 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that...
4D Molecular Therapeutics snagged $90 million in a Series B financing round. The company intends to use the funds to advance its Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics.
Novartis has signed an agreement with Pear Therapeutics to develop and commercialise prescription digital therapeutics for patients with substance and...Read More... The post Sandoz and Pear to create digital therapeutics for opioid use disorders appeared first on Pharmaceutical Technology.
Neon Therapeutics (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. As quoted in the press release: In addition, Neon Therapeutics has granted the underwriters ...
United Therapeutics Corporation has agreed to acquire SteadyMed for $216m. United Therapeutics will purchase SteadyMed for $4.46 a share in...Read More... The post M&As this week: United Therapeutics, Par Formulations, Endo Ventures appeared first on Pharmaceutical Technology.
Drug development company SalvaRX Group offered a business update on Thursday, confirming significant progress for investees iOx Therapeutics and Intensity Therapeutics. iOsx Therapeutics, in which ...
Investor Conference Call on Monday, May 14th at 10:00 am ET NEW YORK and CLEVELAND, May 11, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceuti...
Click Therapeutics, Inc. (“Click”), a provider of Digital Therapeutics solutions as prescription medical treatments, has raised $17 million in funding led by Sanofi Ventures, the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sano...
Alexion Pharmaceuticals is buying Wilson Therapeutics for $855 million. With the company, Alexion will acquire WTX101, Wilson Therapeutics’ Phase III compound for Wilson disease.
Investor Conference Call on Tuesday, March 27th at 10:00 am ET NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharma...
NewsThe companies have entered into a license agreement regarding a collaborative licensing, research, and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB).
Centogene has signed an agreement with Aldeyra Therapeutics for the advancement of novel therapeutics for patients with Sjögren-Larsson Syndrome (SLS).
Three months after securing $100 million in a crossover financing round, Cambridge, Mass.-based Rubius Therapeutics is looking at a $200 million initial public offering to support its personalized red blood cell therapeutics program.
PHILADELPHIA, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced t...
PHILADELPHIA , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sind,...
PTC Therapeutics has signed an agreement to acquire Agilis Biotherapeutics for $945m. Agilis Biotherapeutics’ product pipeline includes four gene therapies programmes...Read More... The post M&As this week: PTC Therapeutics, Cambrex appeared first on Pharmaceutical Technology.
Oxford, UK-based Evox Therapeutics has raised £35 million to help advance its exosome-based therapeutics pipeline.
To treat demyelinating and degenerative diseases of the CNS
- Acquisition adds Zavante’s CONTEPO™, potential first-in-class in the United States injectable antibiotic for cUTIs, to Nabriva’s late-stage anti-infective portfolio - - Nabriva on track to file New Drug Applications for lefamulin and CONTEPO in the fourth quarter of 2018 - - Ted Schroeder appointed as Nabriva’s CEO to continue Nabriva’s path to commercialization; Dr. Colin Broom to...
Partners with Pear Therapeutics to launch FDA-approved apps
NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene ther...